18F-DCFBC Prostate-Specific Membrane Antigen–Targeted PET/CT Imaging in Localized Prostate Cancer

Barış Türkbey, Esther Mena, Liza Lindenberg, Stephen Adler, Sandra Bednarova, Rose Berman, Anita Ton, Yolanda McKinney, Philip Eclarinal, C. Rowland Hill, George Afari, Sibaprasad Bhattacharyya, Ronnie C. Mease, Maria J. Merino, Paula Jacobs, Bradford J. Wood, Peter A. Pinto, Martin G. Pomper, Peter L. ChoykeClinical 2017 · DOI

Abstract

The majority of index prostate cancers are detected with F-DCFBC PET/CT, and this may be a prognostic indicator based on uptake and staging. However, for detecting prostate cancer with high sensitivity, it is important to combine prostate-specific membrane antigen PET/CT with mpMRI.
BibTeX
@inproceedings{turkbey2017f,
  author = {Barış Türkbey and Esther Mena and Liza Lindenberg and Stephen Adler and Sandra Bednarova and Rose Berman and Anita Ton and Yolanda McKinney and Philip Eclarinal and C. Rowland Hill and George Afari and Sibaprasad Bhattacharyya and Ronnie C. Mease and Maria J. Merino and Paula Jacobs and Bradford J. Wood and Peter A. Pinto and Martin G. Pomper and Peter L. Choyke},
  title = {{18F-DCFBC Prostate-Specific Membrane Antigen–Targeted PET/CT Imaging in Localized Prostate Cancer}},
  booktitle = {Clinical},
  year = {2017},
  doi = {10.1097/rlu.0000000000001804},
}

Loading related content...

Figure